Editor’s note: The drugs are listed in alphabetical order.
- Amantadine hydrochloride capsule: Strides Pharma and Teva Pharmaceuticals have both discontinued the 100-milligram presentations of amantadine hydrochloride capsule, an antiviral and neurology medication, based on a business decision, while Teva’s discontinuation follows similar commercial considerations.
- Benazepril hydrochloride capsule: Aurobindo Pharma USA has discontinued the 10-, 20- and 40-milligram presentations of benazepril hydrochloride tablet, used for cardiovascular conditions.
- Gefitinib tablet: Apotex Corp. has discontinued the 250-milligram presentation of gefitinib tablet used in oncology treatments based on commercial reasons.
- Glipizide tablet, extended release: Pfizer and Teva have discontinued multiple presentations of glipizide extended-release tablet, used in endocrinology and metabolism. The decision to discontinue the products was based on business reasons.
- Idarubicin hydrochloride Injection: Pfizer has discontinued the 1-milligram/milliliter presentation of idarubicin hydrochloride injection used for oncology treatments. The product has been replaced with a new NDC number.
- Pirfenidone: Genetech has discontinued the 267-milligram presentation of pirfenidone capsule used for pulmonary/allergy treatments.
- Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated resupply by mid-February, while Alvogen has no estimated release date.
- Varenicline tartrate tablet: Mylan Pharmaceuticals has permanently discontinued multiple strengths of varenicline tablet, a medication used for addiction treatment.